Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study
dc.contributor.author | Roukos, D. H. | en |
dc.contributor.author | Lorenz, M. | en |
dc.contributor.author | Karakostas, K. | en |
dc.contributor.author | Paraschou, P. | en |
dc.contributor.author | Batsis, C. | en |
dc.contributor.author | Kappas, A. M. | en |
dc.date.accessioned | 2015-11-24T18:59:57Z | |
dc.date.available | 2015-11-24T18:59:57Z | |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/19447 | |
dc.rights | Default Licence | - |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Aged, 80 and over | en |
dc.subject | Female | en |
dc.subject | Follow-Up Studies | en |
dc.subject | Gastrectomy/*methods | en |
dc.subject | Humans | en |
dc.subject | Lymph Nodes/*pathology | en |
dc.subject | Lymphatic Metastasis | en |
dc.subject | Male | en |
dc.subject | Middle Aged | en |
dc.subject | Neoplasm Invasiveness | en |
dc.subject | *Neoplasm Recurrence, Local | en |
dc.subject | *Neoplasm Staging | en |
dc.subject | Predictive Value of Tests | en |
dc.subject | Prognosis | en |
dc.subject | Prospective Studies | en |
dc.subject | Risk Assessment | en |
dc.subject | Sensitivity and Specificity | en |
dc.subject | Stomach Neoplasms/*pathology/*surgery | en |
dc.subject | Treatment Outcome | en |
dc.title | Pathological serosa and node-based classification accurately predicts gastric cancer recurrence risk and outcome, and determines potential and limitation of a Japanese-style extensive surgery for Western patients: a prospective with quality control 10-year follow-up study | en |
heal.abstract | UICC classification accurately predicts overall survival but not recurrence-risk. We report here data of overall and first site-specific recurrence following curative surgery useful for the development of recurrence-oriented preventive target therapies. Patients who underwent resection for gastric cancer were stratified according to curability of surgery [curative (R0) vs non-curative resection], extent of surgery [limited (D1) vs extended (D2) node dissection] and pathological nodal/serosal status. The intent-to-treat principle, log-rank test and Cox regression analysis were used for statistical analysis of time-to-event (recurrence, death) endpoints. Curative resection only produced a chance of cure whereas survival was very poor following non-curative resection (P < 0.0001). For D2 R0 subgroup of patients, a pathological serosa and a node state-based classification into three groups, proved to be of clinical implication. Risk of recurrence after a median follow-up of 92 months was low among patients with both serosa and node-negative cancer (first group; 11%), moderate among those with either serosa or node-positive cancer (second group; 53%) and very high among those with both serosa and node-positive cancer (third group; 83%). In multivariate analysis, the relative risks of recurrence and death from gastric cancer among patients in the second and third groups, as compared to those in the first, were 7.07 (95% CI, 2.36-21.17; P = 0.0002) and 16.19 (95% CI, 5.76-45.54; P < 0.0001) respectively. First site-specific recurrence analysis revealed: low rate of loco-regional recurrence alone (12%), serosa state determinant factor of the site-recurrence (peritoneal for serosa-positive and haematogenous for serosa-negative cancers) and dramatic increase of all types of recurrence by the presence of nodal metastases. Our findings demonstrate that a pathological serosa- and node-based classification is very simple and predicts accurately site-specific recurrence-risks. Furthermore they reveal that risk of recurrence following curative D2 surgery alone is low for serosa- and node-negative cancers, but very high in serosa- and node-positive cancers suggesting the need for new therapeutic strategies in this subgroup of patients. | en |
heal.access | campus | - |
heal.fullTextAvailability | TRUE | - |
heal.identifier.primary | 10.1054/bjoc.2001.1720 | - |
heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/11401312 | - |
heal.identifier.secondary | http://www.nature.com/bjc/journal/v84/n12/pdf/6691720a.pdf | - |
heal.journalName | Br J Cancer | en |
heal.journalType | peer-reviewed | - |
heal.language | en | - |
heal.publicationDate | 2001 | - |
heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
heal.type | journalArticle | - |
heal.type.el | Άρθρο Περιοδικού | el |
heal.type.en | Journal article | en |
Αρχεία
Πρωτότυπος φάκελος/πακέτο
1 - 1 of 1
Φόρτωση...
- Ονομα:
- Roukos-2001-Pathological serosa.pdf
- Μέγεθος:
- 99.2 KB
- Μορφότυπο:
- Adobe Portable Document Format
Φάκελος/Πακέτο αδειών
1 - 1 of 1
Φόρτωση...
- Ονομα:
- license.txt
- Μέγεθος:
- 1.74 KB
- Μορφότυπο:
- Item-specific license agreed upon to submission
- Περιγραφή: